Jun 2017 $8 M Private placement after listing $2 to $10 million 3
Transgenomic Inc.: Private sale, Jun 2017 × Investors in this round 3 investors had bought by the notice of Jul 17, 2017: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Carl Iberger · Executive Officer Ilan Danieli · Executive Officer, Director Mark D. Rimer · Director Michael A. Luther · Director Robert M. Patzig · Director Samuel D. Riccitelli · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Shares of Common and Preferred Stock issued pursuant to conversion of outstanding debt.”Signed by Ilan Danieli, Ceo. Source: SEC Form D, newest notice filed Jul 17, 2017. Read the notice at the SEC .
equity SEC Apr 2017 $1 M Private placement after listing Under $2 million 5
Transgenomic Inc.: Private sale, Apr 2017 × Investors in this round 5 investors had bought by the notice of Apr 26, 2017: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $1 M offered; $0 M still to sell
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions $84,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Paul Kinnon · Executive Officer, Director Doit L Koppler · Director Michael L Luther · Director Mya L Thomae · Director Robert M Patzig · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Aegis Capital Corp. (CRD 15007) · New York, New York Sold in CA, CT, NY Remarks in the notice On fees: “Aegis Capital Corp. received warrants to acquire 168,000 shares of Transgenomic, Inc. common stock”Signed by Paul Kinnon, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 26, 2017. Read the notice at the SEC .
debt, options SEC Jan 2016 $2 M Private placement after listing $2 to $10 million 5
Transgenomic Inc.: Private sale, Jan 2016 × Investors in this round 5 investors had bought by the notice of Jan 20, 2016: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $140,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Leon F. Richards · Executive Officer · Chief Accounting Officer Paul Kinnon · Executive Officer, Director · President, Chief Executive Officer, Interim Chief Financial Officer and Secretary, Director Doit L. Koppler, II · Director Michael L. Luther · Director Mya L. Thomae · Director Robert M. Patzig · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, Minnesota Sold in CA, VA Remarks in the notice On fees: “In addition to the above, for $50, the Company issued to Craig-Hallum Capital Group LLC a 5 year warrant to purchase up to 107,527 shares of common stock with an exercise price of $1.21 per share, which will be exercisable beginning on July 8, 2016.”Signed by Leon Richards, Chief Accounting Officer. Source: SEC Form D, newest notice filed Jan 20, 2016. Read the notice at the SEC .
equity, options SEC Jul 2015 $3 M Private placement after listing $2 to $10 million 2
Transgenomic Inc.: Private sale, Jul 2015 × Investors in this round 2 investors had bought by the notice of Jul 17, 2015: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $212,783
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Leon F. Richards · Executive Officer Paul Kinnon · Executive Officer, Director · President, Chief Executive Officer, Interim Chief Financial Officer and Secretary, Director Doit L. Koppler, II · Director John D. Thompson · Director Michael A. Luther · Director Mya A. Thomae · Director Robert M. Patzig · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, Minnesota Sold in CA, MN Remarks in the notice On fees: “In addition to the above, for $50, the Company issued to Craig-Hallum Capital Group LLC a 5 year warrant to purchase up to 107,033 shares of common stock with an exercise price of $1.66 per share, which will be exercisable beginning on January 7, 2016.”Signed by Leon Richards, Chief Accounting Officer. Source: SEC Form D, newest notice filed Jul 17, 2015. Read the notice at the SEC .
equity, options SEC Dec 2014 $2 M Private placement after listing Under $2 million 8
Transgenomic Inc.: Private sale, Dec 2014 × Investors in this round 8 investors had bought by the notice of Jan 26, 2015: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $46,250
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Leon F. Richards · Executive Officer Paul Kinnon · Executive Officer, Director · President, Chief Executive Officer, Interim Chief Financial Officer and Secretary, Director Doit L. Koppler, II · Director John D. Thompson · Director Michael A. Luther · Director Robert M. Patzig · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, Minnesota Sold in IL, MN, NJ, NY Remarks in the notice On fees: “Craig-Hallum Capital Group LLC was issued an unsecured convertible promissory note in an aggregate principal amount of $46,250, which is convertible into shares of the common stock of Transgenomic, Inc., for acting as placement agent for the offering.”Signed by Paul Kinnon, President, CEO, Interim CFO & Secretary. Source: SEC Form D, newest notice filed Jan 26, 2015. Read the notice at the SEC .
debt, options SEC Oct 2014 $2 M Private placement after listing $2 to $10 million 9
Transgenomic Inc.: Private sale, Oct 2014 × Investors in this round 9 investors had bought by the notice of Oct 27, 2014: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Mark P. Colonnese · Executive Officer Paul Kinnon · Executive Officer, Director · President and Chief Executive Officer, Director Doit L. Koppler, II · Director John D. Thompson · Director Michael A. Luther · Director Robert M. Patzig · Director Rodney S. Markin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark P. Colonnese, Executive Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 27, 2014. Read the notice at the SEC .
equity, options SEC Mar 2014 $7 M Private placement after listing $2 to $10 million 3
Transgenomic Inc.: Private sale, Mar 2014 × Investors in this round 3 investors had bought by the notice of Mar 14, 2014: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $7 M of $7 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Mark P. Colonnese · Executive Officer Paul Kinnon · Executive Officer, Director Antonius P. Schuh · Director Doit L. Koppler II · Director Robert M. Patzig · Director Rodney S. Markin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Mark P. Colonnese, Executive Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 14, 2014. Read the notice at the SEC .
equity SEC Jan 2013 $8 M Private placement after listing $2 to $10 million 32
Transgenomic Inc.: Private sale, Jan 2013 × Investors in this round 32 investors had bought by the notice of Feb 6, 2013: 32 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $575,190
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Chad M. Richards · Executive Officer Craig J. Tuttle · Executive Officer, Director · Director, President and Chief Executive Officer Mark P. Colonnese · Executive Officer Antonius P. Schuh · Director Doit L. Koppler Ii · Director Robert M. Patzig · Director Rodney S. Markin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round CRAIG-HALLUM CAPITAL GROUP LLC (CRD 121395) · Minneapolis, Minnesota Sold in CA, CT, IL, MA, MN, NJ, NY, PA, TX, VA, WA LAZARD CAPITAL MARKETS LLC (CRD 134736) · New York, New York Sold in CA, CT, IL, MA, MN, NJ, NY, PA, TX, VA, WA Signed by Mark P. Colonnese, Executive Vice President and Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 6, 2013. Read the notice at the SEC .
equity, options SEC Feb 2012 $22 M Private placement after listing $10 to $50 million 56
Transgenomic Inc.: Private sale, Feb 2012 × Investors in this round 56 investors had bought by the notice of Feb 13, 2012: 56 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $22 M of $22 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,330,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Brett J Frevert · Executive Officer Chad J Richards · Executive Officer Craig J Tuttle · Executive Officer, Director · DIRECTOR, PRESIDENT AND CEO Antonius J Schuh · Director Doit J Koppler Ii · Director Robert J Patzig · Director Rodney J Markin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Craig-Hallum Capital Group LLC (CRD 121395) · Minneapolis, Minnesota Sold in CA, CO, IL, MA, MN, NY, OH, VA, WA, WI, WV Signed by Brett L. Frevert, Chief financial officer. Source: SEC Form D, newest notice filed Feb 13, 2012. Read the notice at the SEC .
equity, options SEC Dec 2011 $3 M No. 1 $2 to $10 million 3
Transgenomic Inc.: Raise no. 1, Dec 2011 × Investors in this round 3 investors had bought by the notice of Jan 13, 2012: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $3 M of $3 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brett L Frevert · Executive Officer · CFO Chad M Richards · Executive Officer · CHIEF COMMERCIAL OFFICER Craig J Tuttle · Executive Officer, Director · DIRECTOR, PRESIDENT AND CEO Antonius P Schuh · Director Doit L Koppler Ii · Director Robert M Patzig · Director Rodney S Markin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Brett L. Frevert, Cfo. Source: SEC Form D, newest notice filed Jan 13, 2012. Read the notice at the SEC .
debt, options SEC Dec 2010 $6 M Issued in a merger or acquisition $2 to $10 million 3
Transgenomic Inc.: Private sale, Dec 2010 × Investors in this round 3 investors had bought by the notice of Jan 10, 2011: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Transgenomic Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue $5 million to $25 million
Sales commissions $100,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Brett Frevert · Executive Officer Chad Richards · Executive Officer Craig Tuttle · Executive Officer, Director Katrina Fahlin · Executive Officer Antonius Schuh · Director Doit Koppler · Director Robert Patzig · Director Rodney Markin · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Griffin Securities, Inc. (CRD 43229) · New York, New York Sold in VA Remarks in the notice On a merger: “Proceeds from the offering were used to finance Transgenomic, Inc.'s acquisition of certain assets of Clinical Data, Inc. and PGxHealth, LLC.”Signed by Craig Tuttle, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 10, 2011. Read the notice at the SEC .
equity, options SEC